

Amendments to the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application, wherein additions are shown in underlined text and deletions are shown in strike-out text:

Claims **1-40** (Cancelled).

Claim **41** (Currently Amended) A method of treating an individual suffering from fibromyalgia and other somatoform disorders, the method comprising the step of administering to the individual a therapeutically effective ~~dose~~ amount of racemic reboxetine or a pharmaceutically acceptable salt thereof ~~to an individual~~.

Claim **42** (Cancelled).

Claim **43** (Cancelled).

Claim **44** (Currently Amended) The method of claim **41** wherein ~~the~~ said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 2 to about 20 mg/day.

Claim **45** (Currently Amended) The method of claim **44** wherein ~~the~~ said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 4 to about 10 mg/day.

Claim **46** (Currently Amended) The method of claim **45** wherein ~~the~~ said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 6 to about 10 mg/day.

Claim **47** (Currently Amended) The method of claim **41** wherein said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered as a composition and said composition is administered orally, parenterally, topically, transdermally, rectally, or vaginally.

Claim 48 (Currently Amended) The method of claim 47 wherein said ~~reboxetine~~ composition is orally administered, and further comprising with a pharmaceutically acceptable carrier comprising at least one of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, and wetting agent.

Claim 49 (Original) The method of claim 48 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim 50 (Currently Amended) The method of claim 47 wherein said ~~reboxetine~~ composition is ~~parenterally~~ parenterally administered subcutaneously, ~~intravenously~~ intravenously, or intramuscularly.

Claim 51 (Original) The method of claim 41 wherein the pharmaceutically acceptable salt is methanesulfonate salt.

Claim 52 (Cancelled).

Claim 53 (Cancelled).

Claim 54 (New) The method of claim 41, wherein the other somatoform disorders are selected from the group consisting of one or more of a somatization disorder, a conversion disorder, a pain disorder, hypochondriasis, a body dysmorphic disorder, an undifferentiated somatoform disorder, and somatoform NOS.